We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Antibodies Aimed at Drugs of Abuse Targets

By LabMedica International staff writers
Posted on 12 Jul 2011
A recently released range of drug-targeted antibodies including anti-haloperidol, anti-methicathinone, anti-norfentanyl, and anti-theophylline has been added to an already impressive catalog of drug-targeted antibodies for research and development applications.

Randox Life Sciences (Crumlin, United Kingdom) has been involved in the development and manufacture of life sciences research products for more than 30 years. Their products include recombinant proteins, polyclonal antibodies, and conjugates targeting drugs of abuse, steroids, hormones, and biochemical markers. These products are manufactured at their ISO 13485 certified manufacturing plant in the United Kingdom.

In the field of drugs of abuse testing, Randox has assembled a large catalog of antibodies and conjugates specific for antidepressants, barbiturates, benzodiazepines, hallucinogens, opiates, sedatives, stimulants, and therapeutic drugs.

Related Links:
Randox Life Sciences






New
Gold Member
Aspiration System
VACUSAFE
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Repetitive Pipette
VWR® Stepper Pro
New
All-in-One Molecular System
AIO M160

Latest BioResearch News

Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
12 Jul 2011  |   BioResearch

Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
12 Jul 2011  |   BioResearch

Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
12 Jul 2011  |   BioResearch